The median methylation level of MGMT in glioma samples was 64.65% (IQR, 54.87%–74.37%) compared to 38.30% (IQR, 34.13%–45.45%) in healthy controls, and all revealed significant differences including P16. This evidence concerns the gene MGMT and central nervous system cancer.